Introduction {#Sec1}
============

Invasive lobular carcinoma (ILC) is the second most common histologic type of breast carcinoma after invasive ductal carcinoma (IDC). In most series ILC constitutes between 5 and 15% of all breast cancers, whereas IDC constitutes between 70 and 90% of all breast cancers \[[@CR1]--[@CR5]\]. Probably due to the use of complete hormone replacement therapy the lobular breast cancer component has continuously increased over the past decade from 9.5% in 1987 to 15.6% in 1999 \[[@CR3]\].

Patients are, according to most series, a little older than patients presenting with IDC, especially the fraction of patients presenting with ILC younger than 40 is smaller \[[@CR1], [@CR5], [@CR6]\]. Furthermore, the mean tumor size of ILC is slightly larger than in patients with IDC and patient presentation with a tumor larger than 5 cm occurs more often in cases of ILC \[[@CR1], [@CR5], [@CR7]\].

Histopathologically, ILC are clearly defined: ILCs are constituted from small, relatively uniform cells, very similar to normal endothelial cells. Characteristically, these cells are only loosely cohesive and infiltrate the stroma in single cell file strands along ductuli. This growth pattern, present in 30--77% of cases \[[@CR8]\], is also known as "Indian filing." It is probably caused by a typical loss of the adhesion molecule E-cadherin. Often there is very little desmoplastic stromal reaction \[[@CR8], [@CR9]\]. The biological characteristics of ILC are usually less alarming than those of IDC: more tumors contain estrogen receptors and progesterone receptors, while expression of Her2/Neu and p53 are more often normal and axillary lymph nodes are not more often positive, even though ILC are overall larger in size than IDC \[[@CR1], [@CR7]\].

Probably due to the diffuse infiltrative growth pattern, ILC is frequently missed on mammography \[[@CR5]\]. Detection is also compromised because ILC often has a density less than or equal to normal fibroglandular breast tissue on mammography \[[@CR5], [@CR10]\].

For correct treatment of ILC, adequate staging is important. Both mammography and ultrasound tend to underestimate lesion size and are therefore not optimal for staging purposes \[[@CR5], [@CR11]\]. This may in part be the reason that higher failure rates of breast-conserving therapy (BCT) in ILC than in IDC are reported \[[@CR2], [@CR11], [@CR12]\]. Various authors therefore propose magnetic resonance imaging (MRI) as the modality of choice for the evaluation of ILC. Several small studies addressing the different aspects of the use of MRI in ILC have been presented, but no large series to date. Therefore many questions regarding the use of MRI in ILC remain unanswered.The sensitivity of MRI for breast lesions is approximately 95--98%, however, whether this holds true for ILC as well is not clear \[[@CR13]\].The morphologic aspects of ILC are not yet well defined, nor is the dynamic behavior of contrast agents in these tumors clearly documented.Moreover, whether the MRI findings are similar to pathologic findings and can thus be used for accurate staging still needs to be established.Finally, the impact of MRI on surgical treatment of ILC should be evaluated.To answer these questions we performed a thorough review of the existing literature regarding the use of MRI in case of ILC and performed meta-analysis whenever possible. We subsequently reviewed the literature on other imaging modalities for this indication in order to evaluate the use of MRI from a clinical perspective.

Materials and methods {#Sec2}
=====================

Search strategy {#Sec3}
---------------

We performed a literature search for articles that specifically dealt with the use of MRI in patients with histologic proof of ILC published before 1 April 2006. The Cochrane Library, MEDLINE and the in-progress citations as provided by PubMed were searched using the query: "lobular AND (MR OR MRI OR MRT OR magnetic)." These databases were further searched using the "Related Articles" function in PubMed. The same query was used to browse the web using scholar.google.com.

Furthermore, the references of all retrieved articles were manually searched for relevant cross-references. Articles in all languages were accepted. All retrieved articles were then compared and from overlapping series of patients only the most recent publication was accepted.

Many different search terms were used for literature review of other imaging modalities. However, only PubMed was used as search engine.

Endpoints {#Sec4}
---------

The study was thus undertaken to answer the following four questions.What is the sensitivity of MRI for ILC?What are the visual characteristics of ILC on MRI?Are the findings on MRI equal to the findings at pathology?What is the impact of MRI on surgical management of ILC?Whenever studies allowed direct comparison between MRI and other imaging modalities, these modalities were also analyzed. Sensitivity was defined as the number of lesions visible on MRI divided by the total number of ILC detected at pathology. We regarded morphology, dynamic curve analysis of contrast behavior, and quantitative dynamic analysis of contrast behavior as three different aspects of tumor appearance and these were thus analyzed separately. A principal distinction between mass-like and non-mass-like lesions was made in the analysis of morphology. Based on the BI-RADS lexicon \[[@CR14]\], we defined architectural distortion, regional, segmental, ductal, multifocal, or diffuse enhancement, and multiple enhancing foci as descriptors of non-mass lesions. Nodular or focal enhancement, well-defined, round, irregular or spiculated masses, and dominant masses with small enhancing foci were defined as descriptors of mass-like lesions. Correlation between the findings on MRI and pathology was evaluated for relative tumor size (unifocal versus multifocal disease and single quadrant versus multicentric disease) and absolute tumor size. The impact on surgical management was derived from all changes implemented, based solely on MRI findings. The numbers of correct and incorrect changes were tabulated.

Eligibility criteria {#Sec5}
--------------------

All studies that presented a series of at least ten patients with histologic proof of pure ILC, with or without concurrent DCIS and/or LCIS, were considered eligible. A quality analysis of the study had to be possible, otherwise no abstracts were accepted. Patients with mixed carcinomas of ILC and IDC were excluded. Studies that presented data on both ILC and mixed carcinomas had to allow extraction of the relevant data for ILC only. Every study considered eligible according to these eligibility criteria was then evaluated for all the study endpoints. Specific eligibility criteria for the various considered endpoints are described below."*Detection*: Studies had to be based on a pathology database and all subsequent patients with ILC who underwent a MRI had to be included. The total number of ILC confirmed at pathology had to be clearly stated as well as the number of lesions found with MRI.*Morphology*: Studies describing the appearance of ILC visible on MRI were eligible. Separation between mass and non-mass-like lesions had to be possible.*Dynamic curve analysis of contrast behavior*: Studies that described the enhancement versus time curve were eligible. However, as time to peak and shape of the final phase of the enhancement curve were our main endpoints, these had to be described.*Quantitative analysis of contrast behavior*: Studies performing quantitative analysis of the contrast-enhancement parameters were eligible.*Relative correlation with pathology*: Studies presenting data on the unifocal versus multifocal correlation or single quadrant involvement versus multicentric involvement were eligible.*Absolute correlation with pathology*: Studies comparing sizes measured on MRI with those measured at pathology and presenting a correlation coefficient or sufficient raw data to calculate such a value were eligible.*Detection of additional lesions*: Any study describing additional lesions apart from the index lesion detected by MRI only with subsequent acquisition of histologic proof of malignancy was considered eligible. Lesions in the ipsilateral breast and the contralateral breast were evaluated separately.*Impact on surgical treatment*: Studies mentioning all changes in surgical strategy based on MRI findings were eligible."

Statistics {#Sec6}
----------

The quality of all included studies was assessed using the QUADAS tool \[[@CR15]\]. The latter is a list of 14 items created for quality assessment of studies to diagnostic accuracy. Although not all the included studies specifically evaluate diagnostic accuracy, this tool was judged to be the most appropriate available. Data of all the studies were collected according to the inclusion and exclusion criteria. When at least five studies presented the same type of data or at least 100 patients were included in a smaller series of studies with similar data, we considered meta-analysis and heterogeneity analysis was performed. Dichotomous data with a binomial distribution (e.g., sensitivity) were transformed to the log odds scale because this scale has a normal distribution and is a good approximation to the exact binomial distribution. A disadvantage of this transformation, however, is that the confidence intervals are a little wider and values in the middle of the distribution (e.g., sensitivity closer to 50%) are more heavily weighted in meta-analysis than values close to the upper or lower level. Pearson's correlation coefficient was transformed to Fisher's *Z* for the same reason \[[@CR16]\].

We calculated Cochran's *Q* coefficient and the *I*^2^-statistic to assess heterogeneity. Cochran's *Q* is a form of the *χ*^2^-test and provides information about the applicability of pooling the data. The *I*^2^-statistic provides a quantitative measure of the amount of heterogeneity and has an upper limit of 100%. Values of the *I*^2^-statistic of 25, 50, and 75% can be interpreted as low, moderate, and high heterogeneity, respectively \[[@CR17]\]. Meta-analysis of the data using a random effects model was performed when the *Q*-coefficient showed no significant heterogeneity (*p* \> 0.05).

In cases where meta-analysis was feasible, the estimate and the 95% CL are expressed. When meta-analysis was not feasible due to severe heterogeneity, only the range of values found in the different studies is mentioned. All calculations were performed using R version 2.3.1 (The R Project for Statistical Computing, www.r-project.org) and the meta package (G. Schwarzer, cran.r-project.org).

Results {#Sec7}
=======

Studies {#Sec8}
-------

We identified 21 separate studies that dealt with MRI and ILC \[[@CR18]--[@CR38]\]. We further identified four studies that did not deal specifically with ILC and MRI. However, they did present their data in such a fashion that relevant information for ILC only could be extracted for at least ten patients \[[@CR39]--[@CR42]\]. Four studies were case-reports and were dropped from the cohort \[[@CR20], [@CR21], [@CR29], [@CR37]\]. The study by Bazzocchi et al. \[[@CR18]\] was excluded because only eight patients underwent MRI. Leung et al. \[[@CR27]\] and Newstead et al. \[[@CR42]\] only published their findings in abstract form and were consequently excluded. Table [1](#Tab1){ref-type="table"} gives an overview of the included studies and their characteristics, including the QUADAS score. Table 1Characteristics of the included studiesAuthorsPub. Year^a^Study type^b^N^c^Age mean^d^Age min.^e^Age max.^f^Field^g^Scan seq.^h^Uni/bilat^i^Compression^j^Mean size^k^QUADAS score^l^Rodenko et al. \[[@CR32]\]19961206038842110X11Sittek et al. \[[@CR34]\]1998123XXX1220X11Weinstein et al. \[[@CR36]\]200111753326922111,712Kim et al. \[[@CR41]\]200111254^m^24^m^88^m^22102,1^m^12Trecate et al. \[[@CR35]\]2001128X32812220X9Francis et al. \[[@CR24]\]2001222XXX22203,712Qayyum et al. \[[@CR30]\]20021135546842110X11Munot et al. \[[@CR28]\]20021206139782320X11Yeh et al. \[[@CR38]\]200311959427922204,111Kneeshaw et al. \[[@CR26]\]20031215743722210X11Quan et al. \[[@CR31]\]200316253XX2231X10Bedrosian et al. \[[@CR39]\]200312453^m^XX2001X10Schelfout et al. \[[@CR33]\]20041265741743220X11Diekmann et al. \[[@CR22]\]2004117XXX0000X10Boetes et al. \[[@CR19]\]200413455357822204,910Berg et al. \[[@CR40]\]2004229XXX3220X13Kepple et al. \[[@CR25]\]20051296251672130X9Fabre Demard et al. \[[@CR23]\]2005134XXX2220X11^a^Year of publication of the original article^b^1 indicates retrospective cohort study, 2 indicates prospective cohort study^c^Number of patients included^d^Mean age of all included patients, X denotes not mentioned^e^Age of respective youngest patient included in the study^f^Age of respective eldest patient included in the study^g^Strength of magnetic field---0 denotes unknown, 1 denotes 1 T, 2 denotes 1.5 T, 3 denotes both 1 T and 1.5 T^h^Type of scan sequence used---0 denotes unknown, 1 denotes RODEO, 2 denotes FLASH 3D, 3 denotes other^i^Unilateral or bilateral imaging of the breast---0 denotes unknown, 1 denotes unilateral, 2 denotes bilateral, 3 denotes both unilateral and bilateral depending on the patient^j^Compression applied to the breast---0 denotes no, 1 denotes yes^k^Mean size of the lesions in centimeters, X denotes not mentioned^l^Number of items valid on QUADAS scorings list^m^Valid for whole study population only, not for subpopulation of patients with ILC

The applied scan protocols in the included studies are diverse. In general, most studies presented herein used a 1.5-T MRI scanner, although some authors had at least some of their included patients scanned using 1.0 T machines \[[@CR33], [@CR34], [@CR40]\]. Most protocols were based on T1 weighted images made with either a normal FLASH 3D sequence or a FLASH 3D sequence with fat-suppression \[[@CR19], [@CR20], [@CR23], [@CR24], [@CR26], [@CR31], [@CR33]--[@CR36], [@CR38], [@CR40], [@CR41]\] or a RODEO sequence with water selective excitation \[[@CR25], [@CR30], [@CR32]\]. A number of authors also used T2 weighted sequences \[[@CR22], [@CR23], [@CR31], [@CR38], [@CR40], [@CR41]\]. Other differences in scan protocols involve the voxel sizes and temporal resolution. Some authors emphasize high spatial resolution \[[@CR32], [@CR39]\] while others prefer high temporal resolution \[[@CR26]\] and yet again others performed both types of sequences in succession \[[@CR30], [@CR38]\]. Furthermore, single breast coils \[[@CR26], [@CR30], [@CR32], [@CR36], [@CR41], [@CR43]\] and double breast coils (all others) were used and sometimes compression was applied to the imaged breast \[[@CR31], [@CR36], [@CR39]\]. In most reported studies the scanning protocols evolved over time and are thus not identical for all imaged patients.

Lesion detection {#Sec9}
----------------

Eight studies provided sufficient data to calculate sensitivity of MRI for ILC \[[@CR19], [@CR23], [@CR24], [@CR26], [@CR28], [@CR33], [@CR34], [@CR40]\]. Sensitivity ranged from 83 to 100%. Cochran's *Q* was 6.48 (*p* = 0.49), *I*^2^ was 0%, indicating homogeneous studies and hence data pooling could be performed. Mean sensitivity was 93.3% (95% CI 88--96%). Only the studies by Francis et al. \[[@CR24]\] and Berg et al. \[[@CR40]\] provided prospective data and are therefore able to show sensitivity in clinical practice. They showed a sensitivity of 95 and 97%, respectively, and were statistically not different from the retrospective studies (two-sided *T*-test, *p* = 0.78). Seven of these studies also provided data on mammography \[*Q* 31.79 (*p* \< 0.001), *I*^2^ = 81%\], six on ultrasound \[*Q* 10.92 (*p* = 0.05), *I*^2^ = 54%\], and five on clinical examination \[*Q* 29.63 (*p* \< 0.001), *I*^2^ = 87%\]. Sensitivity of ultrasound could also be computed through meta-analysis and was 83% (95% CI 71--91%), although moderate heterogeneity was present. The provided data for mammography and clinical examination were too heterogeneous for meta-analysis and ranged from 34 to 91 and 28 to 94%, respectively. Figure [1](#Fig1){ref-type="fig"} shows the results of each independent study and the overall results. Fig. 1Forestplot of the sensitivity of the respective modalities for *ILC* (*MMG* mammography, *US* ultrasound, *CE* clinical examination), the *horizontal lines* represent 95% confidence intervals. Modalities presented on the *right* of the authors name have not been tested in the appropriate study. The *diamonds* at the *bottom* represent the pooled estimates and their 95% confidence intervals for *MRI* and *US*, respectively. Because mammography and clinical examination were too heterogeneous for meta-analysis no pooled estimate is presented for these modalities

Morphology {#Sec10}
----------

Seven studies described lesion morphology on static MRI images \[[@CR23], [@CR30], [@CR32], [@CR33], [@CR36], [@CR38], [@CR41]\]. However, Kim et al. \[[@CR41]\] studied morphologic appearances of masses only and therefore did not include non-mass-like lesions. Information provided by their study is therefore only used to evaluate the appearance of masses and not for the principal distinction between mass and non-mass lesions. The terminology used in the literature to describe the lesions is highly variable. Only Yeh et al. \[[@CR38]\] consistently used the terminology of the BI-RADS lexicon \[[@CR14]\]. The six eligible studies that presented data on morphologic appearance described a total of 133 tumors. However, results are highly variable. The incidence of a mass-like lesion ranged from 31 to 95% \[*Q* 16.44 (*p* \< 0.01), *I*^2^ = 70%\]. Table [2](#Tab2){ref-type="table"} shows the appearance of ILC on MRI for all individual studies. Table 2Morphologic appearance of ILC on MRIAuthorsNumber of tumorsNon-mass-likeMass-likeRodenko et al. \[[@CR32]\]201 (5)19 (95)Weinstein et al. \[[@CR36]\]188 (44)10 (56)Qayyum et al. \[[@CR30]\]139 (69)4 (31)Yeh et al. \[[@CR38]\]2011 (55)9 (45)Schelfout et al. \[[@CR33]\]276 (22)21 (78)Fabre Demard et al. \[[@CR23]\]3511 (31)24 (69)Numbers between parenthesis represent percentages

Fabre Demard et al. \[[@CR23]\] did not specify the lesions beyond the description "mass-like." Other authors used many different terms to further describe lesions. In the study presented by Rodenko et al. \[[@CR32]\], five pre-defined shapes were used, but they described all 19 mass-like lesions as spicular enhancing masses. In the other studies most lesions are described as spiculated masses as well. Schelfout et al. \[[@CR33]\] recognized a dominant mass with multiple enhancing foci in eight cases and Yeh et al. \[[@CR38]\] described even a round focal mass. In the 12 mass-like cases described by Kim et al. \[[@CR41]\], 10 had an irregular shape and 8 were spiculated. Therefore, among the 76 masses, a total of 65 tumors were described as an irregular or spiculated mass. This appears to be the most common type of mass-like presentation in ILC.

Kinetics {#Sec11}
--------

Only two studies reported on the dynamic curve appearance of ILC \[[@CR34], [@CR35]\]. The most apparent similarity between findings was that maximum enhancement is often delayed and wash-out is present in only a minority of lesions. Sittek et al. \[[@CR34]\] reported that maximum enhancement was not reached before 2 min after contrast administration. Trecate et al. \[[@CR35]\] noted that a classic pattern of rapid signal increase was only present in 4 of 12 pure ILC, whereas a delayed pattern was observed in the other 8 cases.

Two other studies reported on quantitative contrast behavior analysis in ILC \[[@CR30], [@CR38]\]. Qayyum et al. \[[@CR30]\] reported on a parameter called K21, analogue to the *K*^trans^ parameter as described by Tofts et al. \[[@CR44]\]. Yeh et al. \[[@CR38]\] evaluated the extraction flow product (EFP), which is a similar analogue but respects the possibility that contrast leakage from the vessels is limited by flow instead of being limited by the permeability surface area product. Both studies did not, however, include sufficient patients to produce meaningful results, other than a high variability in the values of these parameters and the presence in some tumors of enhancement very much like enhancement in normal breast tissue. It was noted that K21 values appeared to be an order of magnitude less in ILC than in IDC lesions.

Correlation {#Sec12}
-----------

Several authors evaluated correlation of the MRI findings with pathology \[[@CR19], [@CR24]--[@CR26], [@CR28], [@CR32], [@CR33], [@CR40]\]. Three studies compared unifocality and multifocality between MRI and pathology \[[@CR26], [@CR32], [@CR33]\] (Table [3](#Tab3){ref-type="table"}). Overall 5 of 67 cases (7%) were regarded as multifocal, whereas they appeared unifocal at pathology and, vice versa, 2 cases (3%) in one study appeared unifocal at MRI, but were multifocal according to pathology. Table 3Relative correlation of unifocality versus multifocality for MRI versus pathologyAuthorsNumber of patientsUF MRIUF PATHMF MRIMF PATHOverestimated^a^Underestimated^b^Rodenko et al. \[[@CR32]\]2091111921Kneeshaw et al. \[[@CR26]\]21910121110Schelfout et al. \[[@CR33]\]261417121021Total6752*UF* unifocal, *MF* multifocal, *PATH* pathology^a^Disease was classified as multifocal on MRI, but was unifocal on pathology^b^Disease was classified as unifocal on MRI, but was multifocal on pathology

Overestimation of multifocality based on mammography in 63 patients from these studies occurred in 2 patients (3%), whereas underestimation occurred 25 times (40%) and the lesion was not visible on mammography in another 4 patients (6%).

Two of these studies further analyzed single quadrant versus multicentric involvement of the affected breast \[[@CR32], [@CR33]\] (Table [4](#Tab4){ref-type="table"}). In the study by Rodenko et al. \[[@CR32]\], two cases of single quadrant disease were erroneously classified as multicentric on MRI. Table 4Relative correlation of single quadrant versus multicentric involvement for MRI versus pathologyAuthorsNumber of patientsSQ MRISQ PATHMC MRIMC PATHOverestimated^a^Underestimated^b^Rodenko et al. \[[@CR32]\]2091111920Schelfout et al. \[[@CR33]\]2621215500Total4620*SQ* single quadrant, *MC* multicentric, *PATH* pathology^a^Multicentric involvement was seen on MRI, but involvement of only one quadrant was shown on pathology^b^Involvement of only one quadrant was seen on MRI, but on pathology multicentric involvement was shown

Mammography in 42 of these patients resulted in overestimation of disease extent in 1 patient and underestimation in 15. Again, no lesion was visible in four patients.

Berg et al. \[[@CR40]\] further showed a series of 12 patients that underwent MRI. Correct size estimation was performed in seven patients. In one patient an additional focus was missed and in four patients overestimation occurred due to foci of LCIS.

Absolute correlation of MRI and pathologic size measurement was performed by six authors \[[@CR19], [@CR24]--[@CR26], [@CR28], [@CR32]\]. Rodenko et al. \[[@CR32]\] found a Kappa coefficient of 0.77, which represents substantial agreement. The other authors presented Pearson's correlation coefficients ranging from 0.81 to 0.97 \[*Q* 10.90 (*p* = 0.03), *I*^2^ = 63%\]. Correlation coefficients for other modalities were substantially more variable. Presented correlation coefficients in Table [5](#Tab5){ref-type="table"} are optimized by excluding cases where no abnormalities were seen from the calculations. Table 5Correlation of tumor size measured by various modalities compared to pathologyAuthorsMRIMMGUSCE*N*PCC*ΚN*PCC*KN*PCC*KN*PCC*K*Rodenko et al. \[[@CR32]\]200.77315−0.081Munot et al. \[[@CR28]\]200.97100.66140.67Kneeshaw et al. \[[@CR26]\]210.86210.93^a^210.93^a^210.47Francis et al. \[[@CR24]\]220.87160.79200.56190.89Boetes et al. \[[@CR19]\]360.81360.34360.24Kepple et al. \[[@CR25]\]330.8890.71*MMG* mammography, *US* ultrasound, *CE* clinical examination, *N* number of lesions visible on the appropriate modality, *PCC* Pearson's correlation coefficient, *K* Kappa value^a^Kneeshaw et al. did not provide a correlation coefficient for either MMG or US, but only one for the combined modalities

Boetes et al. \[[@CR19]\] applied a correctness measure of 1.0 cm to their data and found that MRI underestimated disease extent in 5 of 36 tumors and overestimated extent in 4 cases by more than 1.0 cm. The data provided by Francis et al. \[[@CR24]\] allow a similar calculation. Underestimation occurred in 6 of 22 cases and overestimation occurred in 1.

Additional lesions {#Sec13}
------------------

Five studies focused on the detection of concurrent additional lesions in the affected breast apart from the index lesion only visible by MRI \[[@CR22], [@CR23], [@CR31], [@CR33], [@CR36]\]. In 44 of 146 patients, additional malignant lesions were found \[*Q* 7.20 (*p* = 0.13), *I*^2^ = 44%\]. Additional malignant findings only visible on MRI were present in 32% of cases (95% CI 22--44%). The results of the individual studies are presented in Table [6](#Tab6){ref-type="table"}. Table 6Additional malignant findings in the ipsilateral breast by MRIAuthorsNumber of patientsNumber of additional findingsWeinstein et al. \[[@CR36]\]187Quan et al. \[[@CR31]\]5111Schelfout et al. \[[@CR33]\]269Diekmann et al. \[[@CR22]\]179Fabre Demard et al. \[[@CR23]\]348Total14644Meta-analysis (%)10032

Eight studies, presented in Table [7](#Tab7){ref-type="table"}, reported on findings in the contralateral breast \[[@CR19], [@CR22]--[@CR25], [@CR28], [@CR31], [@CR40]\]. In 12 of 206 patients, unexpected contralateral cancer was discovered exclusively by MRI \[*Q* 2.28 (*p* = 0.94), *I*^2^ = 0%\]. Cases where contralateral cancer was also visible on mammography and/or ultrasound are excluded. Contralateral carcinoma only visible by MRI was present in 7% of patients (95% CI 4--12%). Table 7Additional findings in the contralateral breast by MRIAuthorsNumber of patientsNumber of contralateral findingsFrancis et al. \[[@CR24]\]220Munot et al. \[[@CR28]\]202Quan et al. \[[@CR31]\]535Diekmann et al. \[[@CR22]\]171Boetes et al. \[[@CR19]\]342Berg et al. \[[@CR40]\]150Kepple et al. \[[@CR25]\]140Fabre Demard et al. \[[@CR23]\]342Total20612Meta-analysis (%)1007

Effect on surgical treatment {#Sec14}
----------------------------

Six studies explicitly stated the effect of MRI on the surgical treatment of their patients \[[@CR23], [@CR26], [@CR28], [@CR31], [@CR32], [@CR39]\]. In 160 patients with ILC, a total of 44 changes in surgical management occurred \[*Q* 7.90 (*p* = 0.16), *I*^2^ = 37%\]. Overall, MRI changed the surgical management in 28.3% of cases (95% CI 20--39%). In 24 cases BCT was changed to mastectomy. In nine cases a wider local excision was performed. In the remaining 11 cases the type of change was not further described. Forty-one of 44 changes in surgical management were retrospectively judged necessary based on pathologic findings \[*Q* 1.24 (*p* = 0.94), *I*^2^ = 0%\]. Therefore, 88% of all changes were correct (95% CI 75--95%). In three cases the change in management was retrospectively judged unnecessary based on pathology. The data of the individual studies are presented in Table [8](#Tab8){ref-type="table"}. Table 8Changes in surgical management based solely on MRI findingsAuthorsNumber of patientsNumber of changesCorrect changesIncorrect changesCorrect wider excisionIncorrect wider excisionCorrect mastectomyIncorrect mastectomyRodenko et al. \[[@CR32]\]2087171Munot et al. \[[@CR28]\]20333Kneeshaw et al. \[[@CR26]\]215514Quan et al. \[[@CR31]\]51111156Bedrosian et al. \[[@CR39]\]241192NANANANAFabre Demard et al. \[[@CR23]\]246633Total160444139231Number of changes (%)10028.3Correct changes (%)10088Number of changes and correct changes show the result of meta-analyses*NA* not available

Rodenko et al. \[[@CR32]\] and Kneeshaw et al. \[[@CR26]\] both reported one further unnecessary mastectomy based on MRI outcomes. However, these mastectomies would also have been performed based on the mammography findings and are therefore not only due to the MRI. Berg et al. \[[@CR40]\] also reported that findings on MRI in 12 patients with ILC would have resulted in two unnecessary mastectomies. However, mastectomies were also indicated according to the ultrasound report. Nonetheless they based their treatment on the mammograms only and therefore these mastectomies were not performed.

Discussion {#Sec15}
==========

Studies and quality analysis {#Sec16}
----------------------------

We included 18 studies, but the highest number of studies that could be used to answer a specific endpoint was 8 (sensitivity and contralateral findings). Strong evidence is therefore lacking and this review is thus a clear call for more substantial research in this area. The overall study quality of all studies is, according to the QUADAS score, reasonably high (lowest score = 9/14). However, this tool does not include the study size in the analysis, which was generally low. The tool places a strong emphasis on the relation of the test to the reference standard (typical for observational studies). In all studies, the reference standard was pathology and therefore always acceptable as gold standard. However, the test results (in this case the MRI reports), were never shielded from the pathologist who performed the pathologic evaluation. In studies that were performed to evaluate the visual characteristics of ILC on MRI a thorough description of the pathological examination was, deservedly so, not included \[[@CR23], [@CR30], [@CR32], [@CR33], [@CR36], [@CR38], [@CR41]\]. These studies thus scored a little lower. There are some other drawbacks that must be considered and that are not included in the QUADAS score. Firstly, all but 2 of the included 18 studies were retrospective in nature, and secondly, the applied MRI protocols were largely heterogeneous (see Table [1](#Tab1){ref-type="table"}). However, the presented data were extracted from studies that made use of the various standards in MRI of the breast of the last decade and therefore give a reasonable overview of the overall capability of MRI in ILC imaging in this period.

Sensitivity {#Sec17}
-----------

The sensitivity of physical examination and conventional imaging for ILC of the breast is not optimal. The sensitivity of physical examination for ILC ranges between 65 and 98% \[[@CR10], [@CR45]--[@CR47]\], with usually over 50% of patients presenting with palpable abnormalities.

The sensitivity of mammography for ILC (BI-RADS 3 or higher) ranges between 81 and 92% in literature \[[@CR10], [@CR45]--[@CR51]\]. In a recent study that evaluated intra- and interobserver variability, sensitivity even ranged from 88 to 98% \[[@CR52]\], which could be regarded as sufficient. However, ILC often do not appear as a malignant lesion on mammography; approximately 30% is classified as equivocal and sensitivity is then approximately 57--59% \[[@CR51]\].

The overall sensitivity of mammography in the current analysis appears lower than findings in the literature on mammography in ILC. However, equivocal findings may have been classified as undetected lesions in some studies resulting in the overall lower results. Nevertheless, the sensitivities of only 34% found by Berg et al. \[[@CR40]\], and 50% found by Munot et al. \[[@CR28]\] are on the lower end of the spectrum. Munot et al. \[[@CR28]\] did not state which views constituted their mammograms, while Berg et al. \[[@CR40]\] made craniocaudal, mediolateral and spot-compression views on a standard mammography machine, which we regard as common practice. A possible explanation for the poor results in the study by Berg et al. \[[@CR40]\] may be that they defined an ILC as a focus of tumor, thereby allowing more tumors to be present in one breast, whereas other authors defined this as multifocal or multicentric tumors and thus as detected when at least one lesion was visible on mammography.

In literature, the reported sensitivity of ultrasound for ILC ranges between 68 and 98% \[[@CR47], [@CR53]--[@CR58]\]. As this range is comparable to the range found in the present evaluation, we are of the opinion that an overall sensitivity of 83% is accurate. However, application of newer high-frequency ultrasound transducers may improve sensitivity. Initial series using 7.5 MHz transducers show sensitivities of 68% \[[@CR47]\] and 78% \[[@CR56]\], whereas series that used 10--13 MHz transducers report sensitivities up to 98% \[[@CR57], [@CR59]\].

Contrast-enhanced MRI is nowadays widely accepted as the most sensitive modality for detection of malignancy of the breast. Early reports on overall sensitivity of MRI for breast lesions range from 93 to 100% \[[@CR13], [@CR60]--[@CR63]\]. Thus, the sensitivity of MRI found for ILC in the studies presented herein and the overall sensitivity of 93.3% calculated from these studies are not different from those known for malignancy in the breast in general. The relatively low heterogeneity of all studies describing lesion detection as well as detection of additional lesions in the ipsi- and contralateral breast show that the applied MRI technique only has a minor impact on the ability of MRI to detect lesions.

The overall sensitivity could even be increased to 96% (95% CI 92--98%) if an early study is excluded from the analysis \[[@CR34]\]. This study reported a sensitivity for ILC of only 83%, a discrepancy that may well be explained by the fact that the slice thickness in this study was 4.2 mm, thicker than in any of the other presented studies, which could have had a negative impact on sensitivity. Moreover, 15 of 23 patients in their series were scanned with a FLASH 3D sequence with TR 8.4/TE 3.0, resulting in image acquisition with a phase-shift of water and fat, which might have further decreased their sensitivity, although this was not apparent from their data.

It must be taken into account that the acquired sensitivity in all studies was achieved in cases where prior knowledge of the existence of ILC was present. Mostly because of the retrospective nature of the presented studies, but also because the two prospective studies both included their patients on the basis of histological proof of invasive (lobular) carcinoma by core biopsy. It is therefore not possible to formulate conclusions on the sensitivity of MRI for ILC prior to biopsy. In a large multicenter trial by Bluemke et al. \[[@CR64]\] overall sensitivity for invasive cancer prior to biopsy was 91%, thus it might be expected that sensitivity for ILC prior to biopsy is also slightly lower. However, in most cases the indication for MRI is assessment of disease extent because of inconclusive findings at mammography or ultrasound. In conclusion, the sensitivity of MRI for ILC is higher than that achieved by any other modality, in direct comparison and validated by literature, and is equal to the overall sensitivity of MRI for malignant lesions of the breast. Only modern ultrasound examinations seem to have the ability to approach the performance of MRI in the detection of ILC \[[@CR57]\].

Morphology {#Sec18}
----------

The morphologic appearance of ILC on MRI ranged from 69% non-mass-like lesions to 95% mass-like lesions, thereby raising questions concerning the amount of heterogeneity in the description of morphology of lesions by radiologists. In fact, the general agreement on the description of lesion type according to the BI-RADS lexicon is only moderate \[[@CR14], [@CR65]\]. In the current analysis, this is even further complicated because most authors did not specifically use the BI-RADS lexicon. Additionally, differences in scan techniques may have further affected the appearance of the lesion. However, in keeping with the above, the classification of lesion type is also highly variable on mammography, where the incidence of mass lesions ranges from 32 to 78% \[[@CR10], [@CR45], [@CR46], [@CR48], [@CR50], [@CR51], [@CR55]\].

The vast majority of the mass-like lesions described on MRI are irregular or spicular lesions. The eight patients with a dominant mass surrounded by multiple enhancing foci, as described by Schelfout et al. \[[@CR33]\], may present noncontiguous foci of disease without visible spiculae due to the absence of desmoplastic reaction, which is a well-known histopathological presentation \[[@CR8]\]. In all series only one round mass was described \[[@CR38]\], suggesting this to be a very rare presentation for ILC. This is consistent with findings in mammography by Le Gal et al. \[[@CR10]\], who described a round mass in only 2% of all patients where a mass was present (4/174) while the remainder was either classified as a spicular mass (54%) or poorly defined mass (44%).

Mammographic findings would therefore appear to correlate well with MRI findings. However, only one study allows direct comparison \[[@CR33]\]: of all lesions visible in this study on both mammography and MRI, 78% (18/23) were classified as mass-like by MRI, while only 48% (11/23) were classified as mass-like by mammography. Six masses on MRI were visible as architectural distortion on mammography and two as asymmetric density. In one case a lesion described as spicular mass on mammography was visible on MRI as multiple enhancing foci with interconnecting enhancing strands.

Non-mass-like ILC in mammography are typically described as architectural distortion or asymmetric density. In some cases microcalcifications are present, although these are often related to concurrent surrounding DCIS, sclerosing adenosis or fibrotic changes and might thus not be related to the presence of ILC \[[@CR45], [@CR51], [@CR55]\]. The descriptors currently used for non-mass-like lesions on MRI are diverse and include various types of abnormal enhancement, such as regional, ductal, segmental, and diffuse enhancement. According to Qayyum et al. \[[@CR30]\] the morphologic description of ILC on MRI has a good correlation to histopathologic findings. The non-mass-like presentation might specifically occur in cases where ILC grow in the classic pattern with cells arranged in a linear fashion along the ductuli.

It may thus be concluded that the appearance of most ILC on MRI and mammography is similar: most ILC are mass-lesions that have clear malignant properties. However, the more diffuse growing tumors are characterized by areas of unexpected enhancement and are more difficult to recognize. In a number of cases where no clear mass is visible on mammography, a mass-like lesion may be found on MRI \[[@CR33]\].

Kinetics {#Sec19}
--------

The relatively late contrast enhancement of ILC apparent in all studies presented here and mirrored by the relatively low values of K21 and EFP in the studies by Qayyum et al. \[[@CR30]\] and Yeh et al. \[[@CR38]\] must be taken into account when evaluating ILC. Standard subtraction images, generated from the pre-contrast and the first or second post-contrast acquisitions may be inconclusive as maximum enhancement is not achieved at this point in time and the lesion is thus not yet clearly visible. In fact, false-negative MRI in cases of ILC is usually contributed to inadequate enhancement of the tumor \[[@CR26], [@CR35], [@CR66]\]. The diffuse and often slow tumor growth, not requiring extensive neovascularization, may partly cause this difficult visualization \[[@CR1], [@CR67], [@CR68]\]. This is also clear from the relatively lower amount of vascular endothelial growth factor found in tumors with a lobular histology, which might also indicate a different signaling pathway in the formation of neovascular vessels in ILC, resulting in more mature and thus less leaky capillaries \[[@CR69]\], with consequently diminished or absent contrast enhancement.

Correlation {#Sec20}
-----------

In the herein presented studies overestimation of lesion extent by mammography is rare, yet underestimation is more rule than exception. This is also confirmed by studies that specifically deal with mammography in cases of ILC. Yeatman et al. \[[@CR5]\] showed that mammography underestimated ILC by a mean of 12 mm. Uchiyama et al. \[[@CR51]\] reported 56% of all visible ILC on mammography to be underestimated and Veltman et al. \[[@CR52]\] showed 35--37% of all ILC to be mammographically understaged.

Ultrasound also tends to underestimate tumor size in the studies presented here. This finding is underlined by Tresserra et al. \[[@CR70]\] and more recently by Watermann et al. \[[@CR71]\], who documented a structural underestimation of 5.4 ± 12.2 mm in cases of ILC versus 1.4 ± 12.0 mm for cases of IDC. This might be partly due to the observation that US tends to underestimate larger tumors more than smaller tumors and low grade tumors more than high grade \[[@CR70]\], consistent with the finding that ILC usually presents with slightly larger and less aggressive tumors \[[@CR1], [@CR5], [@CR67], [@CR72]\]. The current analysis shows that there is good correlation of tumor size measured on MRI compared to pathology. The various studies presented only moderately heterogeneous results.

In most cases MRI outperforms mammography and ultrasound in the assessment of disease extent. Most tumors are correctly classified as uni- or multifocal and multicentric disease is only seldom overestimated \[[@CR19], [@CR32]\].

Additional lesions and effect on surgical treatment {#Sec21}
---------------------------------------------------

Especially important in this analysis is the detection of additional lesions apart from the index lesion in patients with ILC. The co-existence of other invasive malignant lesions apart from the index lesion in the ipsilateral breast in 32% of patients only visualized by MRI is high. Moreover, the detection of contralateral cancer in another 7% of patients by MRI only, seems to make MRI indispensable. These findings are confirmed by the rate of change in treatment of the ipsilateral breast based on MRI. The fact that change in treatment was considered correct, as verified by pathologic findings in the specimen, in 88% of cases shows that ILC is often more extensive than appreciated on conventional imaging.

However, various authors have shown that there is no significant difference in disease free survival (DFS) or overall survival (OS) after BCT or mastectomy in patients with breast cancer. Although some authors report more local recurrence in patients with ILC after BCT \[[@CR2], [@CR73]\], most authors showed that there is no difference in DFS or OS after BCT in ILC versus IDC \[[@CR74], [@CR75]\]. On the other hand, Yeatman et al. \[[@CR5]\] reported a higher rate of conversion from lumpectomy to mastectomy in ILC compared to IDC (17.5% versus 6.9%). More recently, Molland et al. \[[@CR68]\] reported similar findings (37.2% versus 22.4%). Hussien et al. \[[@CR2]\] even reported failure of BCT in patients with ILC in 63% (34/54) of patients, resulting in conversion to mastectomy in 76% of failures (26/34). However, a very recent study by Morrow et al. \[[@CR76]\] showed that BCT did not fail more often in patients with ILC when corrected for age and tumor size, although they still observed a trend of more excisions in patients with ILC \[OR 1.58 (0.89--2.79), *p* = 0.12\].

To date, there is no evidence suggesting increase in survival for patients with ILC due to the performance of MRI. What is then the added value of MRI? The rate of recurrence 10 years after BCT followed by radiotherapy is between 7 and 18% and is not significantly different from the rate of recurrence in case of IDC \[[@CR77], [@CR78]\]. However, in view of the MRI findings (additional malignant lesions in 32% of patients), we can only conclude that in a large number of patients with ILC, surgery is not curative but merely debulking. As recurrence rates are fortunately much lower, we must assume that curative treatment is to be expected from adjuvant therapy. Unfortunately, because there is no possibility to determine which additional findings will respond to adjuvant therapy, the detection of additional lesions on MRI currently still requires a change of treatment when malignancy has been proven by core biopsy. This may further reduce the rate of recurrence in patients with ILC and may even improve survival. However, this requires confirmation in future studies.

Conclusion {#Sec22}
==========

Magnetic resonance imaging has a high sensitivity for ILC, not achieved by other imaging modalities. Therefore MRI is helpful in cases where conventional imaging is inconclusive. Morphology is often mass-like and a typical ILC presents as an irregular or spiculated mass. However, asymmetric enhancement that can be ductal, segmental, regional, or diffuse in nature may be the only sign of tumor. MRI measures disease extent with a high reliability. Although underestimation and overestimation of lesion size by MRI still occurs, it is more accurate than size determination by other modalities, indicating often more extensive tumor burden than expected.

The underestimation by other imaging modalities results in more failure of BCT, more re-excisions and more conversion to mastectomy in series where MRI is not used. MRI has an effect on surgical management in that when used to assess disease extent, surgical management was changed in 28.3% of which 88% were judged necessary based on pathology. Larger series of patients are required to confirm the findings of this review; especially evaluation of tumor morphology and dynamic profile seems feasible.
